Standardized Serum-Free Cryomedia Maintain Peripheral Blood Mononuclear Cell Viability, Recovery, and Antigen-Specific T-Cell Response Compared to Fetal Calf Serum-Based Medium
- 1 September 2011
- journal article
- research article
- Published by Mary Ann Liebert Inc in Biopreservation and Biobanking
- Vol. 9 (3), 229-236
- https://doi.org/10.1089/bio.2010.0033
Abstract
The ability to analyze cryopreserved peripheral blood mononuclear cells (PBMCs) from biobanks for antigen-specific T-cell immunity is necessary to evaluate responses to immune-based therapies. Comprehensive studies have demonstrated that the quality of frozen PBMCs is critical and the maintenance of cell viability and functionality by using appropriate cryopreservation techniques is a key to the successful outcome of assays using PBMCs. Different cryomedia additives affect cell viability. The most common additive is fetal calf serum (FCS), although it is widely known that each FCS lot has to be tested before usage to prevent nonspecific stimulation of T-cells. Also, shipping of samples containing FCS is critical because of many import restrictions. Often, dimethyl sulfoxide (DMSO) is added as a cryoprotectant. However, DMSO concentration has to be reduced significantly because of its toxic effect on cells at room temperature. Therefore, we have developed freezing approaches to minimize cytotoxicity of cryoprotectants and maintain T-cell functionality. We compared different additives to the widely used FCS and found bovine serum albumin fraction V to be an appropriate substitute for the potentially immune-modulating FCS. We also found that DMSO concentration can be reduced by the addition of hydroxyethyl starch. Using our serum-free cryomedia, the PBMC recovery was more than 83% and the PBMC viability was more than 98%. Also, the T-cell functionality measured by enzyme-linked immunospot (ELISpot) was optimal after cryopreservation with our new cryomedia. On the basis of our experimental results, we could finally design 2 different, fully working cryomedia that are standardized, serum free, and manufactured under GMP conditions.This publication has 54 references indexed in Scilit:
- Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402Journal of Translational Medicine, 2010
- Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding ProgramCancer Immunology, Immunotherapy, 2010
- Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cellsCancer Immunology, Immunotherapy, 2009
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- On Immunity Against Infections and Vaccines: Credo 2004Scandinavian Journal of Immunology, 2004
- The promise of cancer vaccinesNature Reviews Cancer, 2004
- Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster VirusClinical and Diagnostic Laboratory Immunology, 2001
- Preservation of Lymphocyte Immunophenotype and Proliferative Responses in Cryopreserved Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Donors: Implications for Multicenter Clinical TrialsClinical and Diagnostic Laboratory Immunology, 2000
- Cryopreservation Modifies Flow‐Cytometric Analysis of Hemopoietic CellsVox Sanguinis, 1995
- Het mechanism of the protective action of glycerol against haemolysis by freezing and thawingBiochimica et Biophysica Acta, 1953